Hot Natural Products & Bioactive Compounds
BioCrick offers high-purity natural products and bioactive compounds for scientific research. Our natural product collection includes compounds derived from plants, microorganisms and other biological sources and is widely used in pharmacological, biochemical and drug discovery research.
Natural products remain an important source of bioactive molecules and drug leads. BioCrick provides researchers with high-quality natural product compounds together with catalog numbers, product information and biological activity data.
Hot Products from BioCrick
Showing 33 - 40 of 9359 hot products
| Catalog No. | Product Name |
|---|---|
| BCC1072 | Nelarabine |
|
Nucleoside analog. Metabolized by adenosine deaminase to active metabolite, arabinofuranosylguanine (ara-G). Inhibits DNA synthesis and induces apoptosis. Inhibits growth of human T cell lymphoblastic leukemia cells in vitro and in vivo.
|
|
| BCC1076 | Gemcitabine HCl |
|
Deoxycytidine analog that inhibits DNA synthesis. Metabolized to form gemcitabine triphosphate (dFdCTP) and gemcitabine diphosphate (dFdCDP). dFdCTD inhibits ribonucleotide reductase causing a reduction in cellular nucleotides. dFdCTP is incorporated in DNA resulting in DNA strand termination. Displays antitumor activity <em>in vitro</em> and <em>in vivo</em>.
|
|
| BCC1078 | Clofarabine |
|
Deoxycytidine kinase (dCK) substrate. Phosphorylated to form clofarabine triphosphate, which competes with dATP for DNA polymerase-<span class='symbol'>α</span> and -<span class='symbol'>ε</span> and potently inhibits ribonucleotide reductase (IC<sub>50</sub> = 65 nM). Induces apoptosis by directly altering mitochondrial transmembrane potential. Demonstrates growth inhibition and cytotoxic activity in a variety of leukemias and solid tumors.
|
|
| BCC1080 | Losartan Potassium (DuP 753) |
|
Selective non-peptide angiotensin AT1 receptor antagonist. Inhibits the contractile effects of angiotensin II on rabbit aorta and jugular vein (pA2 = 8.27). Orally active antihypertensive agent.
|
|
| BCC1081 | Fulvestrant |
|
A high affinity estrogen receptor antagonist (IC50 = 0.29 nM), devoid of any partial agonism both in vitro and in vivo. Also high affinity agonist at the membrane estrogen receptor GPER.
|
|
| BCC1083 | Cilnidipine |
|
Cilnidipine is a unique L-type and N-type calcium channel blocker, used for high blood pressure treatment.Dual L- and N-type calcium channel blocker that displays antihypertensive, sympatholytic and neuroprotective activity. Lowers mean blood pressure and reduces the size of cerebral infarction in the rat model of focal brain ischemia.Cilnidipine (10 mM) suppresses the elevation of the ratio induced by 40 mM KCl, and this suppression is effectively inhibited after the treatment with omega-conotoxin GVIA.Cilnidipine reduces Ca(2+) influx via N-type Ca(2+) channels after NMDA receptors activation and then protects neurons against ischemia-reperfusion injury in the rat retina in vivo. Cilnidipine significantly prevents the increase in desmin staining and restores the glomerular podocin and nephrin expression compared with amlodipine in spontaneously hypertensive rat/ND mcr-cp (SHR/ND). Cilnidipine also prevents the increase in renal angiotensin II content, the expression and membrane translocation of NADPH oxidase subunits and dihydroethidium staining in SHR/ND. Cilnidipine (30 mg/kg/d as food admix) treatment suppresses the increase in systolic blood pressure in Dahl salt-sensitive rats. Cilnidipine inhibits the increase in blood urea nitrogen and decrease in creatinine clearance as well as progression of glomerular sclerosis. Cilnidipine reduces plasma norepinephrine level and plasma rennin activity compared with vehicle-treated Dahl S rats. Cilnidipine suppresses the pressor response induced by sympathetic nerve stimulation and angiotensin II in pithed rats. Cilnidipine or omega-conotoxin MVIIA decreases mean blood pressure, but slightly increases heart rate in anesthetized rats. Cilnidipine can affect sympathetic N-type Ca(2+) channels in addition to vascular L-type Ca(2+) channels in antihypertensive doses in the rat in vivo.
|
|
| BCC1084 | Lidocaine |
|
Anasthetic and class Ib antiarrhythmic agent. Blocks voltage-gated sodium channels in the inactivated state.
|
|
| BCC1085 | ABT-751 (E7010) |
|
Antimitotic agent, inhibits microtubule polymerization. Binds to <span class='symbol'>β</span>-tubulin on the colchine site; blocks cell cycle at G<sub>2</sub>M phase and induces apoptosis. Exhibits antitumor activity. Also displays activity in cell lines resistant to vincristine, doxorubicin and cisplatin. Orally bioavailable.
|
|